Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 9—September 2024
Research

Effects of Rotavirus Vaccination Coverage among Infants on Hospital Admission for Gastroenteritis across All Age Groups, Japan, 2011–2019

Author affiliations: Graduate School of Medicine, Kyoto University, Kyoto, Japan (K. Kishimoto, S. Kunisawa, Y. Imanaka); Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan (K. Fushimi); Centre for Health Security, Graduate School of Medicine, Kyoto University, Kyoto (Y. Imanaka)

Cite This Article

Abstract

We assessed the effect of rotavirus vaccination coverage on the number of inpatients with gastroenteritis of all ages in Japan. We identified patients admitted with all-cause gastroenteritis during 2011–2019 using data from the Diagnosis Procedure Combination system in Japan. We used generalized estimating equations with a Poisson distribution, using hospital codes as a cluster variable to estimate the impact of rotavirus vaccination coverage by prefecture on monthly numbers of inpatients with all-cause gastroenteritis. We analyzed 294,108 hospitalizations across 569 hospitals. Higher rotavirus vaccination coverage was associated with reduced gastroenteritis hospitalizations compared with the reference category of vaccination coverage <40% (e.g., for coverage >80%, adjusted incidence rate ratio was 0.87 [95% CI 0.83–0.90]). Our results show that achieving higher rotavirus vaccination coverage among infants could benefit the entire population by reducing overall hospitalizations for gastroenteritis for all age groups.

Gastroenteritis is one of the most common infectious diseases, characterized by rapid onset of diarrhea with or without nausea, vomiting, fever, and abdominal pain (1,2). Enteric viruses and bacteria are major causes of gastroenteritis (3,4), although causes of hospitalizations related to gastroenteritis are often unidentified (5). Gastroenteritis affects persons of all ages and is a leading cause of death worldwide (6,7); younger children, the elderly, and immunocompromised patients in particular are at risk of severe gastroenteritis (811). Gastroenteritis-related hospitalizations and outpatient visits continue to be significant burdens on health systems (3,12,13).

Rotavirus is a leading cause of gastroenteritis and diarrhea, including fatal illnesses, in both young children and persons of all ages (6). A recent systematic review and meta-analysis reported that the pooled rotavirus prevalence was 7.6% (95% CI 6.2%–9.2%) among persons >5 years of age with diarrhea (14). Rotavirus infection is estimated to cause >200,000 deaths annually in children <5 years of age (15). Oral live-attenuated rotavirus vaccines for infants have been implemented worldwide since 2006. The World Health Organization in 2009 recommended routine immunization for all infants to prevent rotavirus disease (16).

In Japan, the rotavirus vaccine was introduced in 2011 to be administered to infants 2–8 months of age. Rotavirus vaccination coverage in Japan gradually increased from 30% in 2012 to 78% in 2019; however, disparity among prefectures in coverage rates remains relatively high (≈30% in 2019) (17). Implementation of rotavirus vaccines has substantially reduced hospitalizations from rotavirus and all-cause acute gastroenteritis in infants and younger children both in Japan and in other countries (1820). Of note, population-based surveillance for rotavirus gastroenteritis hospitalizations after introduction of rotavirus vaccination identified a reduction in age-specific hospitalization rates among children ineligible for rotavirus vaccination because they were above the upper age limit (21). Furthermore, a large study analyzing saved bacterial cultures from fecal samples reported an almost 50% decline in rotavirus prevalence among adults during the peak rotavirus season after the vaccine was introduced (22). Those studies suggest that rotavirus vaccination for infants might indirectly protect older children and adults from rotavirus.

The long-term impacts of rotavirus vaccination on the entire population have not been fully clarified. Given that gastroenteritis constitutes a significant health concern for person in all age groups, analyzing the effects of rotavirus vaccination on older age groups is warranted. Several recent studies investigating long-term trends after rotavirus vaccine introduction have shown the potential indirect protection of rotavirus vaccination against gastroenteritis (23,24). However, those findings of indirect protection in adults lack consistency, and to date, associations between increases in vaccination coverage and indirect impact from vaccination on gastroenteritis remain unclear. We aimed to assess the effect of rotavirus vaccination coverage on the number of all-age hospital inpatients with gastroenteritis in Japan. We also aimed to describe trends in the numbers of inpatients at high risk of severe gastroenteritis as a foundation for better understanding the public health impacts of infant rotavirus vaccination.

This study was approved by the Ethics Committee, Graduate School of Medicine, Kyoto University (approval no. R0135). Research was conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Health, Labour, and Welfare, Japan.

Methods

Data Source

We used the Diagnosis Procedure Combination (DPC) administrative claims database, which is a case-mix classification system used in Japan for reimbursing acute care hospitals under the public medical insurance scheme (25). DPC administrative claims data include information on hospital codes, patient demographics, admission and discharge dates, admission routes, outcomes, primary and secondary diagnoses (based on codes from the International Classification of Diseases 10th Revision [ICD-10]), comorbidities, complications, and claims for medical services (25). We extracted DPC administrative claims data from the database of the DPC Study Group, comprising voluntarily participating hospitals, which account for >50% of all acute inpatients in Japan (26). We obtained data on rotavirus vaccination coverage by prefecture and year as actual measured values from a previous review of rotavirus vaccination in Japan (17).

Study Population and Definitions

We used data from hospitals that had continuously provided DPC data to the DPC Study Group during 2011–2019 to select the study population. We included in the study all hospitalization data that stated a primary diagnosis, diagnosis causing admission, or the most medically resource-intensive diagnosis of all-cause gastroenteritis during January 2011–December 2019. We used date of discharge, rather than date of admission, to determine the number of monthly inpatients because DPC data were generated after discharge. Gastroenteritis was defined by ICD-10 codes A08.x–A09.x. We categorized included patients into 4 age groups: <5, 5–19, 20–59, and ≥60 years. We defined patients as age-ineligible for rotavirus vaccination if they were age ≥1 year in 2011, ≥2 years in 2012, ≥3 years in 2013, ≥4 years in 2014, ≥5 years in 2015, ≥6 years in 2016, ≥7 years in 2017, ≥8 years in 2018, and ≥9 years in 2019. We obtained information on underlying conditions and medications of patients from the database. We defined underlying conditions at admission by ICD-10 codes C00.0-C97 for cancer and B20.x-B24 for HIV and defined immunocompromised patients as those with cancer or HIV or who had received steroids or immunosuppressants. We defined the rotavirus epidemic season as February–April, on the basis of data from previous studies (27,28).

Statistical Analysis

Our primary outcome of interest was the monthly number of inpatients with all-cause gastroenteritis. We presented the results of time-series of monthly gastroenteritis hospitalizations in total, by age group, and among immunocompromised patients. We also presented annual gastroenteritis hospitalizations during the rotavirus epidemic season in total, by age group, and among immunocompromised patients. We estimated the impact of RV vaccination coverage on the basis of monthly number of gastroenteritis hospitalizations generalized estimating equations (GEE) (2931) using a log-link function and Poisson distribution. We performed primary analyses using the GEE model for overall patients, the age-ineligible population, and immunocompromised patients. We further performed prespecified secondary analyses on data only from rotavirus-epidemic seasons. In our analyses, we did not account for repeated admission of the same patient, because we assumed that disease duration is short and recurrence rare among patients with gastroenteritis.

Because the numbers of gastroenteritis hospitalizations had a serial correlation within each hospital because of local characteristics and were therefore not independent, we designated hospital codes as cluster variables in the GEE models. We used an exchangeable correlation structure in the GEE model. We considered monthly gastroenteritis inpatients by hospital as a dependent variable and rotavirus vaccination coverage by prefecture as an independent variable. We included age groups, years, and months as covariates in the adjusted model. We treated rotavirus vaccination coverage by prefecture and year as categorical variables (based on incremental 10% increases in coverage), because we assumed that the relationship between coverage and the primary outcome was nonlinear. We considered coverage <40% to be the reference category because annual mean coverage reached as high as 30% in 2012, the second year of the study period. We also treated the 4 age groups and 12 month–defined groups as categorical variables. We calculated incidence rate ratios (IRRs) and 95% CIs from the GEE model. We considered p values <0.05 statistically significant; all tests were 2-tailed. We conducted statistical analyses using Stata/SE version 16.1 (StataCorp LLC, https://www.stata.com).

Results

We analyzed 294,108 hospitalizations for gastroenteritis from 569 hospitals in all 47 prefectures in Japan during 2011–2019. Among patient characteristics, median age was 41 years (interquartile range [IQR] 9–73 years), and the highest number (38.3%) of patients was in the ≥60-year age group. The proportion of immunocompromised patients was 12.94% (Table 1).

Time-Series of Gastroenteritis Hospitalizations

Figure 1

Time trends in gastroenteritis hospitalizations among different study populations in study of effects of rotavirus vaccination coverage among infants on hospital admission for gastroenteritis across all age groups, Japan, 2011–2019. A) Monthly numbers of gastroenteritis inpatients in the overall population, compared with annual mean rotavirus vaccination coverage. B–F) Monthly numbers of gastroenteritis hospitalizations among different study populations: B) young children <5 years of age; C) older children and adolescents 5–19 years of age; D) adults 20–59 years of age; E) older adults ≥60 years of age; F) immunocompromised persons.

Figure 1. Time trends in gastroenteritis hospitalizations among different study populations in study of effects of rotavirus vaccination coverage among infants on hospital admission for gastroenteritis across all age groups, Japan, 2011–2019....

Figure 2

Annual numbers of gastroenteritis hospitalizations during the rotavirus vaccination epidemic season among different study populations in study of effects of rotavirus vaccination coverage among infants on hospital admission for gastroenteritis across all age groups, Japan, 2011–2019. A) Overall population; B) young children <5 years of age; C) older children and adolescents 5–19 years of age; D) adults 20–59 years of age; E) older adults ≥60 years of age; F) immunocompromised persons.

Figure 2. Annual numbers of gastroenteritis hospitalizations during the rotavirus vaccination epidemic season among different study populations in study of effects of rotavirus vaccination coverage among infants on hospital admission for gastroenteritis...

Annual mean rotavirus vaccination coverage in Japan increased from 30% in 2012 to 78% in 2019 (Figure 1, panel A) (17). Monthly numbers of gastroenteritis inpatients showed seasonality, peaking in winter (November–January). We observed epidemic peaks in December 2012 and December 2016. We found no obvious secular trends in overall gastroenteritis hospitalizations (Figure 1, panel A). We observed a trend of decreasing gastroenteritis hospitalizations among children <5 years of age in the first half of the study period (Figure 1, panel B), but numbers remained relatively stable among older children and adolescents (Figure 1, panel C) and young adults (Figure 1, panel D). We observed a secular trend of increased hospitalizations among adults ≥60 years of age (Figure 1, panel E) and among immunocompromised patients (Figure 1, panel F). Secular trends in the annual numbers of gastroenteritis hospitalizations during rotavirus epidemic seasons varied (Figure 2). We observed a decreasing trend in hospitalizations during rotavirus -epidemic seasons in young children (Figure 2, panel B) and an increasing trend in older adults (Figure 2, panel E) and immunocompromised patients (Figure 2, panel F).

Association of Vaccination Coverage with Monthly Numbers of Gastroenteritis Inpatients

Figure 3

Association between vaccination coverage percentages and gastroenteritis hospitalization from generalized estimating equations analyses in study of effects of rotavirus vaccination coverage among infants on hospital admission for gastroenteritis across all age groups, Japan, 2011–2019. A–C) Annual associations for the overall population (A), the vaccination age-ineligible population (B), and immunocompromised persons (C). D–F) Associations during rotavirus epidemic seasons, February–April, for the overall population (D), vaccination age-ineligible population (E), and immunocompromised persons (F). Dashed lines indicate 95% CIs; gray horizontal lines indicate an incidence rate ratio of 1.0.

Figure 3. Association between vaccination coverage percentages and gastroenteritis hospitalization from generalized estimating equations analyses in study of effects of rotavirus vaccination coverage among infants on hospital admission for gastroenteritis across all...

Among the overall patient population (N = 294,108), higher rotavirus vaccination coverage was associated with reduced monthly gastroenteritis hospitalizations compared with the reference category of <40% coverage. The IRR for gastroenteritis hospitalization was 0.87 (95% CI 0.83–0.90) for vaccination coverage of >80% after adjusting for age group, year, and month (Table 2; Figure 3, panel A). In the age-ineligible population for rotavirus vaccination (n = 247,156), the IRR for gastroenteritis hospitalization was also lower for vaccination coverage of >80% (adjusted IRR 0.90, 95% CI, 0.87–0.94), and the association between coverage and decreased monthly gastroenteritis hospitalizations was not consistently observed when coverage was <80%. (Figure 3, panel B). However, rotavirus vaccination coverage was not associated with changes in monthly gastroenteritis hospitalizations among immunocompromised patients (Figure 3, panel C). Secondary analyses restricted to rotavirus epidemic seasons also revealed associations between vaccination coverage and monthly gastroenteritis hospitalizations (Table 3). IRRs for gastroenteritis hospitalization gradually decreased with increasing vaccination coverage in the overall population (Figure 3, panel D). We found no vaccination coverage–related reduction in IRRs among the population age-ineligible for vaccination (Figure 3, panel E) or immunocompromised patients (Figure 3, panel F).

Discussion

Our study demonstrated the effect of rotavirus vaccination coverage on all-age gastroenteritis hospitalizations in Japan. Overall, we found that higher rotavirus vaccination coverage among infants was associated with lower monthly gastroenteritis hospitalizations for all age groups. We found a decreasing trend in IRRs for gastroenteritis hospitalizations as vaccination coverage increased in the overall population. Those results highlight the impact of coverage levels in understanding the effect of rotavirus vaccination on the entire population. The magnitude of this effect seems to be relatively small, however, with a point estimate of ≈0.9 for IRRs. We also showed trends in gastroenteritis hospitalizations among immunocompromised patients, who are at risk of severe gastroenteritis, after rotavirus vaccination introduction. Of note, rotavirus vaccination coverage was not associated with changes in monthly gastroenteritis hospitalizations among immunocompromised patients. Our results suggest that higher rotavirus vaccination coverage among infants has little effect on reducing gastroenteritis hospitalization in immunocompromised patients.

The findings of this study provide meaningful insights into the indirect protective benefits of rotavirus vaccination. Previous studies have suggested that infant rotavirus vaccination affords indirect protection against rotavirus in unvaccinated persons (2124). Moreover, a multihospital discharge database study showed a lower gastroenteritis hospitalization rate among members of households in which a child had received the rotavirus vaccine (32). Infant rotavirus vaccination may contribute to reducing rotavirus transmission among unvaccinated persons by decreasing the probability of vaccine recipients becoming infected and likelihood of secondary transmission (21,22,32). In addition, the cumulative increase in rotavirus vaccine recipients might potentially lead to a reduction in rotavirus transmission in the entire population. The burden of rotavirus infection in adults compared with children is not well understood (33). Recent reports have highlighted the substantial magnitude of rotavirus in adults with gastroenteritis (6). Furthermore, several large studies have shown reductions in adult hospitalization after vaccination introduction (23,24), although the most affected age group varied among different cohorts, and findings in relation to indirect protection are inconsistent for adults. Taken together, those findings might provide supporting evidence for routine rotavirus immunization of infants and additional clues for understanding disease transmission.

Among major strengths of this study were use of 9-year longitudinal data from >500 hospitals and use of rotavirus vaccination coverage data at the regional level. Several studies of pneumococcal conjugate vaccine have investigated the association between vaccination coverage and indirect protection in the unvaccinated population (34,35). A recent study in Spain found an association between reductions in rotavirus gastroenteritis hospitalizations and regional rotavirus vaccination coverage in children <5 years of age (36). Those studies suggested that use of vaccination coverage data can provide valuable insights into understanding regional variations in vaccination coverage and associations between vaccination coverage and indirect protection. An additional strength of this study was its description of the postvaccination trends in hospitalizations for gastroenteritis among immunocompromised patients.

Among our study’s limitations was an inherent problem with the diagnostic coding of gastroenteritis. Previous studies have shown the relatively low sensitivity in diagnosing gastroenteritis using ICD codes, both in children and adults (37,38). Possible misclassification of the diagnosis might have resulted in underestimation of the incidence rate of gastroenteritis. The effect of this limitation appears to be mitigated, however, because it is likely that any misclassification occurred equally across different levels of vaccination coverage. Another limitation was that we did not investigate the effect of vaccination coverage on rotavirus gastroenteritis hospitalization. We presumed that an analysis restricted only to patients with the diagnosis of rotavirus gastroenteritis would result in further underestimation of incidence because patients with gastroenteritis are typically not routinely tested for rotavirus in clinical settings (39,40). Instead, we performed secondary analyses with a restriction to the rotavirus epidemic season, which demonstrated results consistent with those of the primary analysis.

Another notable limitation of this study was that rotavirus vaccination coverage was obtained at an aggregate level. Heterogeneity in the distribution of vaccination coverage within the prefecture may lead to confounding for the observed association. Thus, to avoid the ecologic fallacy (41), our results should be interpreted with caution. In addition, we lacked information on socioeconomic status, which could affect both childhood vaccination coverage (42,43) and hospitalization rates. Although we used hospital codes as a cluster variable in the GEE models, results do not account for unmeasured confounding factors. The study population selected from hospitals in the DPC Study Group might have introduced selection bias, another potential limitation. The effect of this bias seems to be limited, however, given the broad coverage of the DPC Study Group database in acute inpatient care in Japan (25).

In conclusion, our study assessed the effects of infant rotavirus vaccination coverage on the number of all-age gastroenteritis hospitalizations in Japan and found higher rotavirus vaccination coverage was associated with a decline in gastroenteritis hospitalization in the overall population. However, the effect size was relatively small. Our study also found gastroenteritis hospitalizations among immunocompromised patients were not affected after rotavirus vaccination introduction. Our findings shed light on the importance of rotavirus vaccination coverage and suggest that, by reducing gastroenteritis hospitalizations, rotavirus vaccination among infants might benefit the entire population.

Top

Acknowledgments

This study was supported by grants from the Ministry of Health, Labour and Welfare, Japan (grant nos. 22AA2003 and 23HA2002 to Y.I.) and the Japan Society for the Promotion of Science (grant no. 23H00448 to Y.I.).

Author contributions: K.K.: conceptualization, formal analysis, investigation, methodology, writing (original draft); S.K.: data curation, methodology, writing (review and editing); K.F.: resources, writing (review and editing); Y.I.: funding acquisition, project administration, resources, supervision, writing (review and editing).

Top

References

  1. Bányai  K, Estes  MK, Martella  V, Parashar  UD. Viral gastroenteritis. Lancet. 2018;392:17586. DOIPubMedGoogle Scholar
  2. Hartman  S, Brown  E, Loomis  E, Russell  HA. Gastroenteritis in Children. Am Fam Physician. 2019;99:15965.PubMedGoogle Scholar
  3. Bresee  JS, Marcus  R, Venezia  RA, Keene  WE, Morse  D, Thanassi  M, et al.; US Acute Gastroenteritis Etiology Study Team. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J Infect Dis. 2012;205:137481. DOIPubMedGoogle Scholar
  4. Cardemil  CV, Balachandran  N, Kambhampati  A, Grytdal  S, Dahl  RM, Rodriguez-Barradas  MC, et al. Incidence, etiology, and severity of acute gastroenteritis among prospectively enrolled patients in 4 Veterans Affairs hospitals and outpatient centers, 2016–2018. Clin Infect Dis. 2021;73:e272938. DOIPubMedGoogle Scholar
  5. Lopman  BA, Hall  AJ, Curns  AT, Parashar  UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin Infect Dis. 2011;52:46674. DOIPubMedGoogle Scholar
  6. Troeger  C, Blacker  BF, Khalil  IA, Rao  PC, Cao  S, Zimsen  SRM, et al.; GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18:121128. DOIPubMedGoogle Scholar
  7. Vos  T, Lim  SS, Abbafati  C, Abbas  KM, Abbasi  M, Abbasifard  M, et al.; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:120422. DOIPubMedGoogle Scholar
  8. Tate  JE, Burton  AH, Boschi-Pinto  C, Steele  AD, Duque  J, Parashar  UD; WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:13641. DOIPubMedGoogle Scholar
  9. Chen  Y, Liu  BC, Glass  K, Kirk  MD. High incidence of hospitalisation due to infectious gastroenteritis in older people associated with poor self-rated health. BMJ Open. 2015;5:e010161. DOIPubMedGoogle Scholar
  10. Schmidt-Hieber  M, Bierwirth  J, Buchheidt  D, Cornely  OA, Hentrich  M, Maschmeyer  G, et al.; AGIHO Working Group. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2018;97:3149. DOIPubMedGoogle Scholar
  11. Balachandran  N, Cates  J, Kambhampati  AK, Marconi  VC, Whitmire  A, Morales  E, et al. Risk factors for acute gastroenteritis among patients hospitalized in 5 Veterans Affairs medical centers, 2016–2019. Open Forum Infect Dis. 2022;9:ofac339. DOIPubMedGoogle Scholar
  12. van Dongen  JAP, Rouers  EDM, Schuurman  R, Bonten  MJM, Bruijning-Verhagen  P; RIVAR Study Group. Acute gastroenteritis disease burden in infants with medical risk conditions in the Netherlands. Pediatr Infect Dis J. 2021;40:3005. DOIPubMedGoogle Scholar
  13. Moon  RC, Bleak  TC, Rosenthal  NA, Couturier  B, Hemmert  R, Timbrook  TT, et al. Epidemiology and economic burden of acute infectious gastroenteritis among adults treated in outpatient settings in US health systems. Am J Gastroenterol. 2023;118:106979. DOIPubMedGoogle Scholar
  14. Arakaki  L, Tollefson  D, Kharono  B, Drain  PK. Prevalence of rotavirus among older children and adults with diarrhea: A systematic review and meta-analysis. Vaccine. 2021;39:457790. DOIPubMedGoogle Scholar
  15. Tate  JE, Burton  AH, Boschi-Pinto  C, Parashar  UD; World Health Organization–Coordinated Global Rotavirus Surveillance Network. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62(Suppl 2):S96105. DOIPubMedGoogle Scholar
  16. World Health Organization. Rotavirus vaccines:an update. Wkly Epidemiol Rec. 2009;84:53340.PubMedGoogle Scholar
  17. Tsugawa  T, Akane  Y, Honjo  S, Kondo  K, Kawasaki  Y. Rotavirus vaccination in Japan: Efficacy and safety of vaccines, changes in genotype, and surveillance efforts. J Infect Chemother. 2021;27:9408. DOIPubMedGoogle Scholar
  18. Kobayashi  M, Adachi  N, Miyazaki  M, Tatsumi  M. Decline of rotavirus-coded hospitalizations in children under 5 years: A report from Japan where rotavirus vaccines are self-financed. Vaccine. 2018;36:272732. DOIPubMedGoogle Scholar
  19. Aliabadi  N, Antoni  S, Mwenda  JM, Weldegebriel  G, Biey  JNM, Cheikh  D, et al. Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008-16: findings from the Global Rotavirus Surveillance Network. Lancet Glob Health. 2019;7:e893903. DOIPubMedGoogle Scholar
  20. Mwenda  JM, Hallowell  BD, Parashar  U, Shaba  K, Biey  JN, Weldegebriel  GG, et al. Impact of rotavirus vaccine introduction on rotavirus hospitalizations among children under 5 years of age—World Health Organization African Region, 2008–2018. Clin Infect Dis. 2021;73:16058. DOIPubMedGoogle Scholar
  21. Payne  DC, Staat  MA, Edwards  KM, Szilagyi  PG, Weinberg  GA, Hall  CB, et al.; New Vaccine Surveillance Network (NVSN). Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 2011;53:24553. DOIPubMedGoogle Scholar
  22. Anderson  EJ, Shippee  DB, Weinrobe  MH, Davila  MD, Katz  BZ, Reddy  S, et al. Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis. 2013;56:75560. DOIPubMedGoogle Scholar
  23. Wilson  SE, Rosella  LC, Wang  J, Renaud  A, Le Saux  N, Crowcroft  NS, et al. Equity and impact: Ontario’s infant rotavirus immunization program five years following implementation. A population-based cohort study. Vaccine. 2019;37:240814. DOIPubMedGoogle Scholar
  24. Baker  JM, Tate  JE, Steiner  CA, Haber  MJ, Parashar  UD, Lopman  BA. Longer-term direct and indirect effects of infant rotavirus vaccination across all ages in the United States in 2000–2013: analysis of a large hospital discharge data set. Clin Infect Dis. 2019;68:97683. DOIPubMedGoogle Scholar
  25. Hayashida  K, Murakami  G, Matsuda  S, Fushimi  K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31:111. DOIPubMedGoogle Scholar
  26. Yasunaga  H. Real world data in Japan: Chapter II. The diagnosis procedure combination database. Ann Clin Epidemiolol. 2019;1:76–79.
  27. Suzuki  H, Sakai  T, Tanabe  N, Okabe  N. Peak rotavirus activity shifted from winter to early spring in Japan. Pediatr Infect Dis J. 2005;24:25760. DOIPubMedGoogle Scholar
  28. Tajiri  H, Takeuchi  Y, Takano  T, Ohura  T, Inui  A, Yamamoto  K, et al. The burden of rotavirus gastroenteritis and hospital-acquired rotavirus gastroenteritis among children aged less than 6 years in Japan: a retrospective, multicenter epidemiological survey. BMC Pediatr. 2013;13:83. DOIPubMedGoogle Scholar
  29. Liang  KY, Zeger  SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:1322. DOIGoogle Scholar
  30. Yarnell  CJ, Fu  L, Manuel  D, Tanuseputro  P, Stukel  T, Pinto  R, et al. Association between immigrant status and end-of-life care in Ontario, Canada. JAMA. 2017;318:147988. DOIPubMedGoogle Scholar
  31. Insaf  TZ, Sommerhalter  KM, Jaff  TA, Farr  SL, Downing  KF, Zaidi  AN, et al. Access to cardiac surgery centers for cardiac and non-cardiac hospitalizations in adolescents and adults with congenital heart defects- a descriptive case series study. Am Heart J. 2021;236:2236. DOIPubMedGoogle Scholar
  32. Cortese  MM, Dahl  RM, Curns  AT, Parashar  UD. Protection against gastroenteritis in US households with children who received rotavirus vaccine. J Infect Dis. 2015;211:55862. DOIPubMedGoogle Scholar
  33. Karakusevic  A, Devaney  P, Enstone  A, Kanibir  N, Hartwig  S, Carias  CDS. The burden of rotavirus-associated acute gastroenteritis in the elderly: assessment of the epidemiology in the context of universal childhood vaccination programs. Expert Rev Vaccines. 2022;21:92940. DOIPubMedGoogle Scholar
  34. Chan  J, Gidding  HF, Blyth  CC, Fathima  P, Jayasinghe  S, McIntyre  PB, et al. Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study. PLoS Med. 2021;18:e1003733. DOIPubMedGoogle Scholar
  35. Oyewole  OR, Lang  P, Albrich  WC, Wissel  K, Leib  SL, Casanova  C, et al. The impact of pneumococcal conjugate vaccine (PCV) coverage heterogeneities on the changing epidemiology of invasive pneumococcal disease in Switzerland, 2005–2019. Microorganisms. 2021;9:1078. DOIPubMedGoogle Scholar
  36. Ruiz-Contreras  J, Alfayate-Miguelez  S, Carazo-Gallego  B, Onís  E, Díaz-Munilla  L, Mendizabal  M, et al. Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013-2018. BMC Infect Dis. 2021;21:1138. DOIPubMedGoogle Scholar
  37. Hsu  VP, Staat  MA, Roberts  N, Thieman  C, Bernstein  DI, Bresee  J, et al. Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalizations in children. Pediatrics. 2005;115:7882. DOIPubMedGoogle Scholar
  38. Pindyck  T, Hall  AJ, Tate  JE, Cardemil  CV, Kambhampati  AK, Wikswo  ME, et al. Validation of acute gastroenteritis–related International Classification of Diseases, Clinical Modification Codes in pediatric and adult US populations. Clin Infect Dis. 2020;70:24237. DOIPubMedGoogle Scholar
  39. Patel  MM, Tate  JE, Selvarangan  R, Daskalaki  I, Jackson  MA, Curns  AT, et al. Routine laboratory testing data for surveillance of rotavirus hospitalizations to evaluate the impact of vaccination. Pediatr Infect Dis J. 2007;26:9149. DOIPubMedGoogle Scholar
  40. Cardemil  CV, O’Leary  ST, Beaty  BL, Ivey  K, Lindley  MC, Kempe  A, et al. Primary care physician knowledge, attitudes, and diagnostic testing practices for norovirus and acute gastroenteritis. PLoS One. 2020;15:e0227890. DOIPubMedGoogle Scholar
  41. Wakefield  J. Ecologic studies revisited. Annu Rev Public Health. 2008;29:7590. DOIPubMedGoogle Scholar
  42. Pearce  A, Law  C, Elliman  D, Cole  TJ, Bedford  H; Millennium Cohort Study Child Health Group. Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study. BMJ. 2008;336:7547. DOIPubMedGoogle Scholar
  43. Kuroda  H, Goto  A, Kawakami  C, Yamamoto  K, Ito  S, Kamijima  M, et al.; Japan Environment and Children’s Study (JECS) Group. Association between a single mother family and childhood undervaccination, and mediating effect of household income: a nationwide, prospective birth cohort from the Japan Environment and Children’s Study (JECS). BMC Public Health. 2022;22:117. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Cite This Article

DOI: 10.3201/eid3009.240259

Original Publication Date: August 13, 2024

Table of Contents – Volume 30, Number 9—September 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Yuichi Imanaka, Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

Send To

10000 character(s) remaining.

Top

Page created: July 31, 2024
Page updated: August 20, 2024
Page reviewed: August 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external